Literature DB >> 29577968

Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia.

Roberto Cangemi1, Roberto Carnevale2, Cristina Nocella2, Camilla Calvieri3, Vittoria Cammisotto1, Marta Novo1, Valentina Castellani1, Alessandra D'Amico2, Chiara Zerbinati2, Lucia Stefanini1, Francesco Violi4.   

Abstract

Previous reports suggest that community-acquired pneumonia (CAP) is associated with an enhanced risk of myocardial infarction (MI) and that enhanced platelet activation may play a role. Aims of this study were to investigate if urinary excretion of 11-dehydro-thromboxane (Tx) B2, a reliable marker of platelet activation in vivo, was elevated in CAP and whether glucocorticoid administration reduced platelet activation. Three-hundred patients hospitalized for CAP were recruited and followed-up until discharge. Within the first 2 days from admission, urinary 11-dehydro-TxB2 and serum levels of methylprednisolone and betamethasone were measured. 11-Dehydro-TxB2 was also measured in a control group of 150 outpatients, matched for age, sex, and comorbidities. Finally, in-vitro studies were performed to assess if glucocorticoids affected platelet activation, at the same range of concentration found in the peripheral circulation of CAP patients treated with glucocorticoids. Compared to controls, CAP patients showed significantly higher levels of 11-dehydro-TxB2 (110 [69-151] vs. 163 [130-225] pg/mg creatinine; p < 0.001). During the in-hospital stay, 31 patients experienced MI (10%). A COX regression analysis showed that 11-dehydro-TxB2 independently predicted MI (p = .005). CAP patients treated with glucocorticoids showed significantly lower levels of 11-dehydro-TxB2 compared to untreated ones (147 [120-201] vs. 176 [143-250] pg/mg creatinine; p < 0.001). In vitro, glucocorticoids-treated platelets showed a dose-dependent decrease of ADP-induced platelet aggregation, TxB2 production, cPLA2 phosphorylation and arachidonic acid release from the platelet membrane. In conclusion, platelet TxB2 is overproduced in CAP patients and may be implicated in MI occurrence. Glucocorticoids reduce platelet release of TxB2 in vitro and urinary excretion of 11-dehydro-TxB2 in vivo and may be a novel tool to decrease platelet activation in this setting.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glucocorticoids; Myocardial infarction; Platelet activation; Pneumonia; Thromboxane B2

Mesh:

Substances:

Year:  2018        PMID: 29577968     DOI: 10.1016/j.phrs.2018.03.014

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  2 in total

1.  Effect of corticosteroids on myocardial injury among patients hospitalized for community-acquired pneumonia: rationale and study design. The colosseum trial.

Authors:  Francesco Violi; Camilla Calvieri; Roberto Cangemi
Journal:  Intern Emerg Med       Date:  2019-05-31       Impact factor: 3.397

Review 2.  Platelets and Their Role in the Pathogenesis of Cardiovascular Events in Patients With Community-Acquired Pneumonia.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.